Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias
Eugene Nikitin, Maria Kislova, Dmitry Morozov, V. V. Belyakova, Anna Suvorova, Julia Sveshnikova, Galina Vyscub, И. В. Матвеева, Maria Shirokova, A.L. Shipaeva, Tatyana Klitochenko, Polina Makarovskaya, Е. А. Дмитриева, Bella Biderman, Andrey Sudarikov, Tatyana Obukhova, Olga Samoilova, Kamil Kaplanov, Tatyana Konstantinova, Olga A. Mayorova, I V Poddubnaya, В. В. Птушкин
Topics & Concepts
IbrutinibMedicineRituximabInternal medicineNeutropeniaRefractory (planetary science)GastroenterologyChronic lymphocytic leukemiaAutoimmune hemolytic anemiaAdverse effectPure red cell aplasiaAnemiaLymphomaLeukemiaOncologyChemotherapyPhysicsAstrobiologyChronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentImmunodeficiency and Autoimmune Disorders